|
|
Article: UC researcher uses historical control group for new osteoporotic fracture analysis.
- Article from:
- Women's Health Weekly
- Article date:
- August 22, 2002
CopyrightCOPYRIGHT 2002 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2002 AUG 22 - (NewsRx.com & NewsRx.net) -- In a new analysis of a study funded by Procter & Gamble Pharmaceuticals, Nelson Watts, MD, professor of medicine at the University of Cincinnati (UC) and director of the UC Bone Health and Osteoporosis Center, has applied an innovative new method for analyzing fracture efficacy for an osteoporosis therapy in a study that was conducted without a placebo control group.
The original study was intended to compare two different dose forms of Actonel (risedronate sodium tablets) for the treatment and prevention of osteoporosis in postmenopausal women, and thus did not have a placebo control group.
Watts constructed a ...